49. ARV Therapy: When and What to Start and When to Switch
Session: Symposium: HIV State of the Art
Thursday, October 27, 2016: 9:00 AM
Room: 393-396
Joel Gallant, MD, MPH, FIDSA, Southwest CARE Center, Santa Fe, NM


Disclosures:

J. Gallant, AbbVie: Investigator , Research support
Bristol-Myers Squibb: Investigator and Scientific Advisor , Consulting fee and Research support
Gilead Sciences: Investigator and Scientific Advisor , Consulting fee and Research support
Janssen Therapeutics: Investigator and Scientific Advisor , Consulting fee and Research support
Merck & Co.,: Investigator and Scientific Advisor , Consulting fee and Research support
Sangamo Biosciences: Investigator , Research support
ViiV Healthcare/GlaxoSmithKline: Investigator and Scientific Advisor , Consulting fee and Research support

See more of: HIV State of the Art
See more of: Symposium
<< Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.